Role of tumor necrosis factor-alpha inhibition with inflixiMAB in cancer therapy and hematopoietic stem cell transplantation

被引：56

作者：

Couriel, DR ^{[1
]}

Hicks, K ^{[1
]}

Giralt, S ^{[1
]}

Champlin, RE ^{[1
]}

机构：

[1] Univ Texas, MD Anderson Canc Ctr, Div Med, Dept Blood & Marrow Transplantat, Houston, TX 77030 USA

来源：

CURRENT OPINION IN ONCOLOGY | 2000年 / 12卷 / 06期

关键词：

D O I：

10.1097/00001622-200011000-00011

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Tumor necrosis factor (TNF)-alpha is a central cytotoxic and proinflammatory cytokine, Research on the benefits of TNF-alpha inhibition as a form of therapy has focused almost exclusively on autoimmune, inflammatory disorders. InflixiMAB, a chimeric antibody to human TNF-alpha, was recently approved for the management of Crohn disease and rheumatoid arthritis. The potential applications of inflixiMAB in the management of cancer are just beginning to be explored. This article reviews the biology, mechanism of action, pharmacology, and toxicity of inflixiMAB. Existing clinical experience and inflixiMAB's potential role as an immunosuppressant and antitumor agent in the management of cancer are also discussed. Curr Opin Oncol 2000, 12:582-587 (C) 2000 Lippincott Williams & Wilkins, Inc.

引用

页码：582 / 587

页数：6

共 50 条

[41] THE LIMITED PROTEOLYSIS OF TUMOR NECROSIS FACTOR-ALPHA
NARHI, LO
RHODE, MF
HUNT, P
ARAKAWA, T
JOURNAL OF PROTEIN CHEMISTRY, 1989, 8 (05): : 669 - 677
[42] The role of tumor necrosis factor-alpha in the pathogenesis of anorexia and bulimia nervosa, cancer cachexia and obesity
Holden, RJ
Pakula, IS
MEDICAL HYPOTHESES, 1996, 47 (06) : 423 - 438
[43] Tumor necrosis factor-alpha: a neuromodulator in the CNS
Pan, WH
Zadina, JE
Harlan, RE
Weber, JT
Banks, WA
Kastin, AJ
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS, 1997, 21 (05): : 603 - 613
[44] TUMOR NECROSIS FACTOR-ALPHA IN INFECTIOUS MENINGITIS
NADAL, D
LEPPERT, D
FREI, K
GALLO, P
LAMCHE, H
FONTANA, A
ARCHIVES OF DISEASE IN CHILDHOOD, 1989, 64 (09) : 1274 - 1279
[45] Eicosanoids and tumor necrosis factor-alpha in the kidney
Ferreri, Nicholas R.
Hao, Shoujin
Pedraza, Paulina L.
Escalante, Bruno
Vio, Carlos P.
PROSTAGLANDINS & OTHER LIPID MEDIATORS, 2012, 98 (3-4) : 101 - 106
[46] Serum erytropoietin in patients with rheumatoid arthritis treated with infliximab, tumor necrosis factor-alpha antagonist
Widuchowska, M
Wiecek, A
Kucharz, EJ
ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 : 302 - 302
[47] A Case of Severe MAGIC Syndrome Treated Successfully With the Tumor Necrosis Factor-Alpha Inhibitor Infliximab
Geissal, Erik D.
Wernick, Richard
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2010, 16 (04) : 185 - 187
[48] Potent inhibition of tumor necrosis factor-alpha by tetrafluoro-thalidomide and tetrafluorophthalimides
Niwayama, S
Turk, B
Liu, J
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1996, 212 : 140 - MEDI
[49] Effect of infliximab, a tumor necrosis factor-alpha inhibitor, on doxorubicin-induced nephrotoxicity in rats
Abdelrahman, Aly M.
Al Suleimani, Yousuf M.
Manoj, Priyadarsini
Ashique, Mohammed
Ali, Badreldin H.
Schupp, Nicole
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2020, 393 (01) : 121 - 130
[50] Cardiopulmonary effects of tumor necrosis factor-alpha in the piglet: Influence of cyclooxygenase inhibition
Osiovich, H
Goldberg, RN
Suguihara, C
Adams, JA
Martinez, O
Kuo, G
Feuer, WI
Offenbacher, S
Bancalari, E
BIOLOGY OF THE NEONATE, 1995, 68 (05): : 342 - 353

← 1 2 3 4 5 →